Sijbrand Hofker.

Hjalmar C. Van Santvoort, M edpillsotc.com .D., Marc G. Besselink, M.D., Ph.D., Olaf J. Bakker, M.D., H. Sijbrand Hofker, M.D., Marja A. Boermeester, M.D., Ph.D., Cornelis H. Dejong, M.D., Ph.D., Harry van Goor, M.D., Ph.D., Alexander F. Schaapherder, M.D., Ph.D., Casper H. Van Eijck, M.D., Ph.D., Thomas L. Bollen, M.D., Bert van Ramshorst, M.D., Ph.D., Vincent B. Nieuwenhuijs, M.D., Ph.D., Robin Timmer, M.D., Ph.D., Johan S.D., Ph.D., Philip M. Kruyt, M.D., Eric R. Manusama, M.D., Ph.D., Erwin van der Harst, M.D., Ph.D., George P. Van der Schelling, M.D., Ph.D., Tom Karsten, M.D., Ph.D., Eric J. Hesselink, M.D., Ph.D., Cornelis J. Van Laarhoven, M.D., Ph.D., Camiel Rosman, M.D., Ph.D., Koop Bosscha, M.D., Ph.D., Ralph J. De Wit, M.D., Ph.D., Alexander P.

The price of thromboembolic occasions was 10.2 percent among sufferers who received rFVIIa in comparison with 8.7 percent among individuals who received placebo . Whenever we evaluated the prices of thromboembolic events regarding to type , we found a considerably higher proportion of arterial thromboembolic events in the rFVIIa-treated groupings than in the placebo groups . No factor was observed between patients who received rFVIIa and sufferers who received placebo with regards to the incidence of venous thromboembolic occasions .